Analysts Start to Turn Against Valeant After Worst Day Ever

Analysts Start to Turn Against Valeant After Worst Day Ever


One of Valeant Pharmaceuticals International Inc.'s biggest sell-side supporters downgraded her rating on the company's stock Wednesday, following other analysts who are starting to turn against the drugmaker after a 51 percent drop in the shares Tuesday. Shibani Malhotra, an analyst with Nomura Securities, cut her rating on the shares to neutral and gave a $60 12-month price target.



from Biotech News